---
title: "WBDE: The first subject has been enrolled in the Phase II/III clinical trial of Shishanjianjia controlled-release tablets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255175145.md"
description: "WBDE announced that the Phase II/III clinical trial of its wholly-owned subsidiary WBDE Pharmaceutical Group Co., Ltd.'s donepezil controlled-release tablets for the treatment of mild to moderate Alzheimer's disease has completed the enrollment of the first subject. The drug utilizes a biphasic controlled-release technology aimed at improving the onset speed and safety of the medication, and supports once-daily dosing to enhance patient convenience and compliance. This trial will validate its clinical value and provide new options for Alzheimer's disease treatment"
datetime: "2025-08-29T10:21:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255175145.md)
  - [en](https://longbridge.com/en/news/255175145.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255175145.md)
---

# WBDE: The first subject has been enrolled in the Phase II/III clinical trial of Shishanjianjia controlled-release tablets

WBDE announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., has completed the enrollment of the first subject in the Phase II/III pivotal registration clinical trial of the Class 2 new drug Huperzine A controlled-release tablets for the treatment of mild to moderate Alzheimer's disease dementia. Huperzine A controlled-release tablets utilize a biphasic controlled-release technology to smooth the drug release peak and trough curve, extending the drug release time in the body, thereby achieving rapid onset, reducing adverse reactions, and enhancing the dosage with good safety. At the same time, the controlled-release technology supports once-daily dosing, improving patient convenience and long-term adherence. This clinical trial will comprehensively validate the overall clinical value and benefits of Huperzine A controlled-release tablets, providing new options for Alzheimer's disease treatment

### Related Stocks

- [002082.CN](https://longbridge.com/en/quote/002082.CN.md)

## Related News & Research

- [Realtor.com names Peabody, Massachusetts top US “hottest” ZIP code for 2026 housing demand](https://longbridge.com/en/news/295388430.md)
- [CATL Battery for Electric Aviation Passes Important Safety Test](https://longbridge.com/en/news/295459818.md)
- [METALS-Aluminium climbs for 6th straight session as inventory draw continues](https://longbridge.com/en/news/295386433.md)
- [13:44 ETCalidar Completes First-in-Human Study of Eidos Prism™ and Advances Toward 2027 Pivotal Study](https://longbridge.com/en/news/295695587.md)
- [14:18 ETUnited Solar Welcomes U.S. Section 232 Measures on Polysilicon](https://longbridge.com/en/news/295697667.md)